Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034922.xml
Arthritis und Rheuma 2024; 44(02): 87-94
DOI: 10.1055/a-2214-4940
DOI: 10.1055/a-2214-4940
Schwerpunkt
CAR-T-Zell-Therapie bei autoimmunen Erkrankungen
ZUSAMMENFASSUNG
Chimeric-Antigen-Receptor(CAR)-T-Zellen haben das Feld der Hämato-Onkologie revolutioniert und kommen seit 2021 auch im Bereich der Autoimmunerkrankungen zur Anwendung. Patienteneigene T-Zellen werden mit einem künstlich hergestellten T-Zell-Rezeptor („CAR“) transfiziert, woraufhin diese den B-Zell-Marker CD19 (oder auch andere Oberflächenmarker) erkennen. Nach Rückgabe der modifizierten T-Zellen nach erfolgter lymphodepletierender Chemotherapie kommt es zu einer raschen Expansion der CAR-T-Zellen. Diese ist mit potenziellen typischen Komplikationen wie dem Cytokine-Release-Syndrome und Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome assoziiert. Die Wirkweise der CAR-T-Zell-Therapie ist noch nicht endgültig erklärt. Das verbesserte Ansprechen von Patienten wird aufgrund des weitverbreiteten Markers CD19 sowie des zellulären Elements der CAR-T-Zellen erklärt. Bislang existieren nur Fallberichte/-serien. Die Erfolge müssen sich nun in klinischen Studien – welche weltweit anlaufen – bestätigen.
Publication History
Article published online:
16 April 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Mackensen A, Muller F, Mougiakakos D. et al Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022; 28: 2124-2132 DOI: 10.1038/s41591-022-02017-5.
- 2 Mougiakakos D, Kronke G, Volkl S. et al CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med 2021; 385: 567-569 DOI: 10.1056/NEJMc2107725.
- 3 Pecher AC, Hensen L, Klein R. et al CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome. JAMA 2023; 329: 2154-2162 DOI: 10.1001/jama.2023.8753.
- 4 Muller F, Boeltz S, Knitza J. et al CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 2023; 401: 815-818 DOI: 10.1016/S0140-6736(23)00023-5.
- 5 Bergmann C, Muller F, Distler JHW. et al Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis 2023; 82 (08) 1117-1120 DOI: 10.1136/ard-2023-223952.
- 6 Taubmann J, Knitza J, Muller F. et al Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T-cells after failure of several B cell depleting antibodies. Rheumatology (Oxford) 2024; 63 (01) e12-e14 DOI: 10.1093/rheumatology/kead330.
- 7 Merkt W, Freitag M, Claus M. et al Third-generation CD19.CAR-T cell-containing combination therapy in Scl70 + systemic sclerosis. Ann Rheum Dis. 2023 Dec 22:ard-2023–225174 DOI: 10.1136/ard-2023-225174
- 8 Frey N. Cytokine release syndrome: Who is at risk and how to treat. Best Pract Res Clin Haematol 2017; 30: 336-340 DOI: 10.1016/j.beha.2017.09.002.
- 9 Lee DW, Santomasso BD, Locke FL. et al ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 2019; 25: 625-638 DOI: 10.1016/j.bbmt.2018.12.758.
- 10 Hunter BD, Jacobson CA. CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions. J Natl Cancer Inst 2019; 111: 646-654 DOI: 10.1093/jnci/djz017.
- 11 Schaefer A, Huang Y, Kittai A. et al Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T). Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience. Cancer Manag Res 2021; 13: 8901-8906 DOI: 10.2147/CMAR.S321202.
- 12 Fried S, Avigdor A, Bielorai B. et al Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 2019; 54: 1643-1650 DOI: 10.1038/s41409-019-0487-3.
- 13 Alexander T, Ostendorf L, Biesen R. et al Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosus. Ann Rheum Dis 2023; 82: 1497-1499 DOI: 10.1136/ard-2023-224152.
- 14 Ostendorf L, Burns M, Durek P. et al Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N Engl J Med 2020; 383: 1149-1155 DOI: 10.1056/NEJMoa2023325.
- 15 Scheibe F, Ostendorf L, Pruss H. et al Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur J Neurol 2022; 29: 1847-1854 DOI: 10.1111/ene.15266.
- 16 Cohen SB, Emery P, Greenwald MW. et al Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-2806 DOI: 10.1002/art.22025.
- 17 Mena-Vazquez N, Redondo-Rodriguez R, Rojas-Gimenez M. et al Efficacy and Safety of Rituximab in Autoimmune Disease-Associated Interstitial Lung Disease: A Prospective Cohort Study. J Clin Med 2022: 11 DOI: 10.3390/jcm11040927
- 18 Rovin BH, Furie R, Latinis K. et al Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-1226 DOI: 10.1002/art.34359.
- 19 Merrill JT, Neuwelt CM, Wallace DJ. et al Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233 DOI: 10.1002/art.27233.
- 20 Gomez Mendez LM, Cascino MD, Garg J. et al Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clin J Am Soc Nephrol 2018; 13: 1502-1509 DOI: 10.2215/CJN.01070118.
- 21 Kamburova EG, Koenen HJ, Borgman KJ. et al A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant 2013; 13: 1503-1511 DOI: 10.1111/ajt.12220.
- 22 van Dam LS, Oskam JM, Kamerling SWA. et al Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients. Front Immunol 2020; 11: 566732 DOI: 10.3389/fimmu.2020.566732.
- 23 Mitsdoerffer M, Di Liberto G, Dotsch S. et al Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity. Brain 2021; 144: 1697-1710 DOI: 10.1093/brain/awab093.
- 24 Gupta S, Simic M, Sagan SA. et al CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity. Neurol Neuroimmunol Neuroinflamm 2023: 10 DOI: 10.1212/NXI.0000000000200080
- 25 Riet T, Chmielewski M. Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges. Front Immunol 2022; 13: 934343 DOI: 10.3389/fimmu.2022.934343.
- 26 Zhang Q, Lu W, Liang CL. et al Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance. Front Immunol 2018; 09: 2359 DOI: 10.3389/fimmu.2018.02359.
- 27 Blat D, Zigmond E, Alteber Z. et al Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther 2014; 22: 1018-1028 DOI: 10.1038/mt.2014.41.
- 28 Adabi N, Pordel S, Rezaee MA. et al Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment. J Gene Med 2023; 25: e3484 DOI: 10.1002/jgm.3484.
- 29 Lee J, Lundgren DK, Mao X. et al Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Invest 2020; 130: 6317-6324 DOI: 10.1172/JCI138416.